



US010888605B2

(12) **United States Patent**  
**Moeller et al.**

(10) **Patent No.: US 10,888,605 B2**  
(45) **Date of Patent: Jan. 12, 2021**

(54) **GLP-1 COMPOSITIONS AND USES THEREOF**

FOREIGN PATENT DOCUMENTS

(71) Applicant: **Novo Nordisk A/S**, Bagsvaerd (DK)

(72) Inventors: **Eva Horn Moeller**, Alleroed (DK);  
**Michael Duelund Soerensen**, Soeborg (DK); **Joakim Lundqvist**, Malmoe (SE)

(73) Assignee: **Novo Nordisk A/S**, Bagsvaerd (DK)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **16/774,666**

(22) Filed: **Jan. 28, 2020**

(65) **Prior Publication Data**

US 2020/0164042 A1 May 28, 2020

**Related U.S. Application Data**

(63) Continuation of application No. PCT/EP2018/072835, filed on Aug. 24, 2018.

(30) **Foreign Application Priority Data**

Aug. 24, 2017 (EP) ..... 17187676

(51) **Int. Cl.**

**A61K 38/26** (2006.01)

**A61K 9/00** (2006.01)

**A61K 9/08** (2006.01)

**A61K 47/02** (2006.01)

**A61K 47/10** (2017.01)

(52) **U.S. Cl.**

CPC ..... **A61K 38/26** (2013.01); **A61K 9/0019** (2013.01); **A61K 9/08** (2013.01); **A61K 47/02** (2013.01); **A61K 47/10** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61K 38/26**; **A61K 9/0019**; **A61K 47/10**;  
**A61K 9/08**; **A61K 47/02**  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,169,771 A 12/1992 Christner et al.  
9,764,003 B2 9/2017 Jensen  
2006/0178304 A1 8/2006 Juul-Mortensen et al.  
2009/0156478 A1\* 6/2009 Lau ..... A61P 3/10  
514/1.1  
2012/0208755 A1 8/2012 Leung  
2016/0235855 A1 8/2016 Xiong et al.

JP	2015522573 A	8/2015
WO	9010020 A1	9/1990
WO	9217482 A1	10/1992
WO	9824767 A1	6/1998
WO	0069413 A1	11/2000
WO	0101774 A1	1/2001
WO	0102369 A2	1/2001
WO	2005042488	5/2005
WO	2005044294	5/2005
WO	2005081711	9/2005
WO	2006055603	5/2006
WO	2006072065	7/2006
WO	2006/097537 A2	9/2006
WO	2006096461	9/2006
WO	2006099561	9/2006
WO	2007075720	7/2007
WO	2007094893	8/2007
WO	2008019115	2/2008
WO	2009051992	4/2009
WO	2011069629	6/2011
WO	2012107476 A1	8/2012
WO	2012151248	11/2012
WO	2013072406	5/2013
WO	2013151663	10/2013
WO	2013151668	10/2013
WO	2013190384	12/2013
WO	2014060472 A1	4/2014
WO	2014182950	11/2014
WO	2015009616	1/2015
WO	2016001862	1/2016

OTHER PUBLICATIONS

BASF: "BASF Chemical Emergency Medical Guidelines," Jan. 1, 2016, Retrieved from the Internet: URL: [https://www.basf.com/documents/corp/en/sustainability/employees-and-society/employees/occupational-medicine/medical-guidelines/PhenoI\\_B\\_BASF\\_medGuidelines\\_E104.pdf](https://www.basf.com/documents/corp/en/sustainability/employees-and-society/employees/occupational-medicine/medical-guidelines/PhenoI_B_BASF_medGuidelines_E104.pdf), retrieved on Nov. 20, 2017.

Lau et al., Journal of Medicinal Chemistry, 2015, vol. 58, No. 18, pp. 7370-7380.

Marbury et al., "Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Once-Weekly Human GLP-1 Analogue, in Subjects With and Without Renal Impairment," Diabetologia, 2014, vol. 57, Supplement: 1, pp. S358-S359.

\* cited by examiner

Primary Examiner — Sudhakar Katakam

(74) Attorney, Agent, or Firm — Rosemarie R. Wilk-Orescan

(57) **ABSTRACT**

The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.

**14 Claims, No Drawings**